Bernstein SocGen Group adjusted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), increasing it slightly from $441.00 to $444.00 while maintaining a Market Perform rating. With a ...

Piper Sandler expressed continued confidence in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), maintaining an Overweight ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...

Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Unfortunately, an equal-sized group of patients got a placebo instead, and they saw their pain decrease, too, by a statistically indistinguishable amount as compared to the Vertex drug.

Vertex Resource Group Ltd. provides environmental and industrial services in Canada and the United States. The company operates through Environmental Consulting and Environmental Services segments.

Vertex Pharmaceuticals via AP The average time to meaningful pain relief ranged from two to four hours, compared to eight hours in the placebo group. Journavx works by inhibiting the NaV1.8 pain ...